Regenx Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The Company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The Company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, Regenxoffers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers.

Employee Rating

3.5More
TypePublic
HQRockville, US
Founded2009
Size (employees)107 (est)+13%
Websiteregenxbio.com
Regenxbio was founded in 2009 and is headquartered in Rockville, US
Report incorrect company information

Key People/Management at Regenxbio

Ken Mills

Ken Mills

President and Chief Executive Officer
Vit Vasista

Vit Vasista

CFO
Stephen Yoo

Stephen Yoo

Chief Medical Officer
Olivier Danos

Olivier Danos

Chief Scientific Officer
Curran Simpson

Curran Simpson

Senior Vice President, Technical Operations
Kimberly Sloan

Kimberly Sloan

Senior Vice President, Human Resources
Show more

Regenxbio Office Locations

Regenxbio has an office in Rockville
Rockville, (HQ)
100 9712 Medical Center Dr
Show all (1)
Report incorrect company information

Regenxbio Financials and Metrics

Regenxbio Revenue

Regenxbio's revenue was reported to be $10.39 m in FY, 2017
USD

Revenue (Q3, 2018)

5.3m

Gross profit (Q3, 2018)

4.8m

Gross profit margin (Q3, 2018), %

90.3%

Net income (Q3, 2018)

(19.2m)

EBIT (Q3, 2018)

(22.7m)

Market capitalization (4-Dec-2018)

2.0b

Closing stock price (4-Dec-2018)

54.6

Cash (30-Sep-2018)

142.4m
Regenxbio's current market capitalization is $2 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

7.6m4.6m10.4m

General and administrative expense

11.9m23.6m27.2m

R&D expense

17.3m45.5m57.2m

Operating expense total

30.7m69.9m86.3m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m393.0k2.4m125.0k455.0k6.6m1.3m132.4m40.0m5.3m

Cost of goods sold

3.9m517.0k

Gross profit

36.2m4.8m

Gross profit Margin, %

90%90%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

54.1m24.8m46.7m

Accounts Receivable

1.0m473.0k

Current Assets

118.1m93.4m168.0m

PP&E

538.0k9.3m14.0m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(22.8m)(63.0m)(73.2m)

Depreciation and Amortization

80.0k544.0k2.7m

Accounts Payable

590.0k186.0k2.6m

Cash From Operating Activities

(22.5m)(48.6m)(58.0m)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(17.6m)(10.8m)(25.2m)(43.4m)(22.0m)(36.5m)(57.2m)104.2m114.8m95.6m

Depreciation and Amortization

43.0k48.0k104.0k264.0k554.0k1.3m2.0m834.0k1.7m2.7m

Accounts Payable

317.0k(182.0k)930.0k3.6m2.5m2.7m1.1m477.0k(340.0k)156.0k

Cash From Operating Activities

(18.1m)(7.9m)(16.3m)(28.1m)(17.5m)(27.0m)(44.2m)58.1m128.3m108.8m
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

Regenxbio Online and Social Media Presence

Embed Graph
Report incorrect company information

Regenxbio News and Updates

Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR

This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…

Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Regenxbio Blogs

REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

Clinical trial evaluates one-time treatment for wet AMD using NAV AAV8 gene therapy A total of 24 patients have been dosed at leading retinal surgery centers in the United States Jeffrey Heier, M.D., to present additional interim Phase I results during the Retina Subspecialty Day at AAO 2018

REGENXBIO Announces Proposed Public Offering Of Common Stock

ROCKVILLE, Md. , Aug. 8, 2018 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell,

REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Aug. 1, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will host a conference call

Regenxbio Company Life and Culture

Report incorrect company information

Regenxbio Frequently Asked Questions

  • When was Regenxbio founded?

    Regenxbio was founded in 2009.

  • Who are Regenxbio key executives?

    Regenxbio's key executives are Ken Mills, Vit Vasista and Stephen Yoo.

  • How many employees does Regenxbio have?

    Regenxbio has 107 employees.

  • What is Regenxbio revenue?

    Latest Regenxbio annual revenue is $10.4 m.

  • What is Regenxbio revenue per employee?

    Latest Regenxbio revenue per employee is $97.1 k.

  • Who are Regenxbio competitors?

    Competitors of Regenxbio include Oxford Genetics, Arbutus Biopharma and Encoded Genomics.

  • Where is Regenxbio headquarters?

    Regenxbio headquarters is located at 100 9712 Medical Center Dr, Rockville.

  • Where are Regenxbio offices?

    Regenxbio has an office in Rockville.

  • How many offices does Regenxbio have?

    Regenxbio has 1 office.